FDA Expected to Lift Peptide Restrictions: What Traders Need to Know Right Now The FDA is expected to lift longstanding restrictions on certain peptides, according to a report from The New York Times — and the market is already pricing in the reversal. For traders positioned in biotech, compounding pharmacy plays, or pharmaceutical sector ETFs, this is not a background news item. This is a catalyst. The expected regulatory shift would reverse a controversial crackdown that began in 2023, when the FDA moved certain peptides — including popular compounds like BPC-157, TB-500, and others used widely in anti-aging and recovery medicine — onto its “bulk drug substances” restricted list. That move hammered compounding pharmacies and sparked immediate legal challenges. Now, with the FDA expected to lift those restrictions, the sector is watching for a clean reversal with significant upside for the right plays. ...